- Home
- TCBIO vs SNN Comparison
TCBIO vs SNN Comparison
Compare TCBIO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBIO
- SNN
- Stock Information
- Founded
- TCBIO N/A
- SNN 1856
- Country
- TCBIO United States
- SNN United Kingdom
- Employees
- TCBIO 1987
- SNN N/A
- Industry
- TCBIO Major Banks
- SNN Industrial Specialties
- Sector
- TCBIO Finance
- SNN Health Care
- Exchange
- TCBIO Nasdaq
- SNN Nasdaq
- Market Cap
- TCBIO N/A
- SNN 12.4B
- IPO Year
- TCBIO N/A
- SNN 1999
- Fundamental
- Price
- TCBIO $21.32
- SNN $29.44
- Analyst Decision
- TCBIO
- SNN Strong Buy
- Analyst Count
- TCBIO 0
- SNN 1
- Target Price
- TCBIO N/A
- SNN N/A
- AVG Volume (30 Days)
- TCBIO N/A
- SNN 674.7K
- Earning Date
- TCBIO N/A
- SNN 08-01-2024
- Dividend Yield
- TCBIO N/A
- SNN 2.55%
- EPS Growth
- TCBIO N/A
- SNN 39.77
- EPS
- TCBIO N/A
- SNN 0.35
- Revenue
- TCBIO N/A
- SNN $5,642,000,000.00
- Revenue This Year
- TCBIO N/A
- SNN $6.92
- Revenue Next Year
- TCBIO N/A
- SNN $5.43
- P/E Ratio
- TCBIO N/A
- SNN $41.81
- Revenue Growth
- TCBIO N/A
- SNN 5.48
- 52 Week Low
- TCBIO N/A
- SNN $21.53
- 52 Week High
- TCBIO N/A
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- TCBIO 53.15
- SNN 46.87
- Support Level
- TCBIO $21.15
- SNN $28.26
- Resistance Level
- TCBIO $21.49
- SNN $29.64
- Average True Range (ATR)
- TCBIO 0.34
- SNN 0.36
- MACD
- TCBIO 0.00
- SNN 0.05
- Stochastic Oscillator
- TCBIO 73.68
- SNN 58.65
About TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.